GOLDMAN SACHS GROUP INC - CRINETICS PHARMACEUTICALS IN ownership

CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 139 filers reported holding CRINETICS PHARMACEUTICALS IN in Q2 2023. The put-call ratio across all filers is 19.18 and the average weighting 0.3%.

Quarter-by-quarter ownership
GOLDMAN SACHS GROUP INC ownership history of CRINETICS PHARMACEUTICALS IN
ValueSharesWeighting
Q3 2023$16,434,265
+48.3%
552,598
-10.1%
0.00%
+50.0%
Q2 2023$11,079,525
+32.6%
614,846
+18.2%
0.00%0.0%
Q1 2023$8,354,379
+242.4%
520,198
+290.2%
0.00%
+100.0%
Q4 2022$2,439,683
+1.3%
133,316
+8.7%
0.00%0.0%
Q3 2022$2,409,000
+32.6%
122,668
+25.9%
0.00%
Q2 2022$1,817,000
-25.2%
97,453
-11.9%
0.00%
-100.0%
Q1 2022$2,428,000
+38.9%
110,603
+79.8%
0.00%
Q4 2021$1,748,000
+49.8%
61,520
+11.0%
0.00%
Q3 2021$1,167,000
+1.7%
55,425
-8.8%
0.00%
Q2 2021$1,147,000
-38.7%
60,805
-50.3%
0.00%
Q1 2021$1,870,000
+3.4%
122,352
-4.5%
0.00%
Q4 2020$1,809,000
+13.8%
128,182
+26.4%
0.00%
Q3 2020$1,589,000
+545.9%
101,392
+622.0%
0.00%
Q2 2020$246,000
-77.5%
14,043
-80.7%
0.00%
Q3 2019$1,093,000
-75.8%
72,640
-59.9%
0.00%
-100.0%
Q2 2019$4,525,000
+1279.6%
180,990
+1157.7%
0.00%
Q1 2019$328,000
-0.3%
14,391
+31.1%
0.00%
Q4 2018$329,00010,9740.00%
Other shareholders
CRINETICS PHARMACEUTICALS IN shareholders Q2 2023
NameSharesValueWeighting ↓
Vivo Capital, LLC 3,375,169$76,819,0007.66%
RA Capital Management 1,875,209$42,680,0001.84%
Perceptive Advisors 2,587,953$58,901,0001.66%
EMORY UNIVERSITY 97,035$2,209,0001.55%
New Leaf Venture Partners, L.L.C. 167,700$3,817,0001.05%
Orbimed Advisors 1,914,282$43,569,0000.67%
Opaleye Management Inc. 73,000$1,661,0000.46%
Novo Holdings A/S 135,009$3,073,0000.46%
Virtus ETF Advisers LLC 7,934$181,0000.38%
Eventide Asset Management 384,000$8,740,0000.30%
View complete list of CRINETICS PHARMACEUTICALS IN shareholders